Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
@ Bermudashorts I appreciate your post very much. Yes, such a shame that this wasn’t available back then. This could change so many peoples destiny’s.
Looking at the trades you can see the slapdown sells from the shorts on any buying volume
Chemo is actually very effective. It is just very debilitating and dosing has to be limited. Some companies like Avacta are working on using more precise methods of delivery to target the tumour and not the rest of the body.
StayLong
I'm so sorry to read your post, it certainly brings home that investments in all bios are about so much more than just money and profit. We are at the start of a new era in oncology with immunotherapies such as checkpoint inhibitors, huge advances in the molecular understanding of tumours and the tumour microenvironment leading to targeted therapies and now live biotherapeutics. Many of these breakthroughs were discovered by small bios and funded by shareholders. So sorry that none of these arrived in time for your Wife, but hopefully one day, chemo will be a thing of the past.
I am so sorry to hear that.
It's crazy that there are so many people whose treatment is currently delayed that could possibly benefit from 0518, which has so far proven to be completely safe. The potential benefits of it working would outweigh the risk that the treatment didn't work if there were no other options.
I think your word phenomenal is correct.
In February of 2006 my wife was diagnosed with stage 3 lung cancer. It was inoperable and basically the only treatment available was chemotherapy and a prayer that cure would come along in time. She spent the following 7 months in absolute pain and misery until she wasted away. She was only 41. If this treatment was around at least she could have spent those 7 seven months with some quality of life and without having to deal with the horrendous side effects of chemotherapy. And who knows yet, but a good chance that this new approach to cancer could have prolonged her life even further maybe a possible chance of a cure. If this was around back then I would have done anything possible to get her on this treatment.
Re the neo adjuvant monotherapy (taking 0518 instead of chemo prior to surgery) I will need to take another look at the previous presentation to see what the discussion was of genetic changes in the tumour.
If you haven't already take a look at the SITC presentation on the website
https://www.4dpharmaplc.com/en/investors/reports-presentations
I think the biomarkers discussed will be based on further analysis of the first set of data from the initial part of the 0518 Keytruda trial. They mentioned the value of doing this in a recent presentation as it will provide further evidence of the mechanism of action of 0518. All very important for any FDA submissions and also future trial planning for 0518.
And you are definitely right about the tumour reductions in patients who were no longer responding to Keytruda and had no other treatment options. The 0518 data from the first trial was phenomenal and one of the main reasons I am so heavily invested here. In addition to lung cancer I think there were also reductions in renal cell carcinoma.
Hi Sanji
Am I right in thinking that the two titles of the presentations are very bold Statements? Baseline biomarkers associated with clinical benefit in patients with solid tumors refractory to immune checkpoint inhibitors (ICIs) treated with live biotherapeutic MRx0518 in combination with pembrolizumab.
And did I read in a previous RNS that the have seen significant changes( reduction) in tumours with patients that have lung cancer that were at the stage that nothing else could be done ?
Yes, I do believe a break is coming and that 90p will be the new support on the way back up
Last few days there does seem to be a new buyer on the scene.
Seems to be US based. All started when the OTC stock was listed in the US (not the LBPS Nasdaq one).
On July 4th holiday there was a brief spike because the algos were on hols for the day
Sanji you say it is short algos controlling the price. Who is doing these short algos? Is it private investors like me or professionals or shorters? Just wondering who would want to keep the price down.
The same thing happened twice last year. The first time it was disrupted because buying firepower was enough to beat them down mainly led by Richard Griffiths.
The second was the news of the Nasdaq listing, which increased interest and buying.
So unless there is news or you can get a buying consortium together it will carry on treading water.
It's not resistance. It's short algos controlling the price. Every time there's a flurry of buys they dump shares.
It's been going on for months.
A little resistance at 90p
move through here and up this goes.
find it hard to believe we are not over the £
This indicates lots of confidence presenting on such a platform.
Presenting in Mid-September on oncology so clearly the data is beginning to take shape. Hopefully a sign of some more news flow to come! Happy to wait.